КАЛЛОП Дара Й. (US),НИКОЛАЕВ Анатолий (US),ТЕССЬЕ-ЛАВИНЬ Марк (US),УЭЙМЕР Робби (US)
申请号：
RU2012124093/15
公开号：
RU2012124093A
申请日:
2010.11.12
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. A method for increasing the density of the patients dendritic spines in neurons with cognitive or mental disorder, comprising administering to said patient an effective amount of DR6 p75 inhibitor or inhibitor.2. The method of claim 1, wherein said inhibitor is a DR6 antibody which binds DR6 and inhibits an epitope DR6 function.3. The method of claim 1, wherein said p75 inhibitor is an antibody that binds to an epitope of the p75 and inhibits p75 function.4. The method of claim 2, wherein said antibody is selected from the group consisting of the 3F4.4.8, 4B6.9.7, 1E5.5.7, and antigen-binding fragments.5. The method of claim 4, wherein said antibody is a chimeric or humanized 3F4.4.8, 4B6.9.7, or 1E5.5.7, or an antibody that binds the same epitope as the 3F4.4.8, 4B6.9.7, or 1E5.5.7.6. The method of claim 1, wherein said DR6 inhibitor reduces or prevents the signal from passing to said DR6 neuron.7. The method of claim 1, wherein the p75 inhibitor reduces or prevents the passage of signals from p75 in said neuron.8. A method of treating cognitive or mental disorders in a patient in need thereof, comprising identifying a patient having cognitive or mental disorder associated with reduced number of dendritic spines, and administering to said patient a therapeutically effective amount of a DR6 antagonist or an antagonist of p75.9. The method of claim 1 or 8, wherein said mental or cognitive disorder is selected from the group consisting of Rett Syndrome, Tourettes syndrome, autism, mental retardation, schizophrenia and related syndrome, fragile X chromosome.10. The method of claim 8, wherein said inhibitor is a DR6 antibody which binds DR6 and inhibits an epitope DR6 function.11. The method of claim 8, wherein said p75 inhibitor is an antibody that binds to an epitope of the p75 and inhibits p75 function.12. The method of claim 10, wherein said antibody is selected from the group consisting of the 3F4.4.8, 4B6.9.7, 1E5.5.7, and antigen-binding fragments.13. The meth
